Does Recent Weakness At Lloyds Banking Group PLC, Reckitt Benckiser Group Plc & AstraZeneca plc Make Them ‘Screaming Buys’?

Royston Wild examines whether share pickers should stock up on Lloyds Banking Group PLC LON: LLOY), Reckitt Benckiser Group Plc (LON: RB) and AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three FTSE fallers that should attract the glances of savvy bargain seekers.

Lloyds Banking Group

Banking colossus Lloyds (LSE: LLOY) have endured a torrid time during the past few months, and shares have shed 8% since the start of August alone. Although the ‘Black Horse’ has recovered some ground in recent days, I reckon Lloyds still provides plenty of value for those seeking quality at rock-bottom prices.

One of the causes behind reduced investor appetite during the summer was the shock £1.4bn charge suffered during the second quarter to cover PPI claims, a colossal charge that took the total cost of the scandal to more than £13bn. But as Investec notes, “Lloyds may, in part, have chosen to ‘go large’ in order to optimise its usage of the final window for tax relief against provisions for redress payments.”

And with the UK economy still ticking reliably higher — a factor that helped underlying profit advance 15% in April-June, to £4.38bn — the City expects Lloyds’ earnings to rise 5% in the current year alone, resulting in an ultra-low P/E multiple of 8.9 times. And with the bank’s capital strength also steadily improving, a total dividend of 2.6p per share is currently pencilled in, yielding a chunky 3.3%.

Reckitt Benckiser

The economic turbulence being witnessed in China has rocked demand for household goods leviathan Reckitt Benckiser (LSE: RB) in recent weeks — the firm has shed 6% of its value during the past month as a result. Still, I believe this presents a prime buying opportunity as the long-term forecasts for consumer spending in developing regions like China remain compelling.

Reckitt Benckiser, which sources a third of total revenues from emerging markets, saw like-for-like sales rise 5% during January-June, to £4.36bn, thanks to solid demand across the globe. The company has also doubled-down on innovation in brands like Durex condoms — the number one contraceptive label in China — to help push sales higher. Acquisitions like that of lubricant maker K-Y earlier this year have helped drive the top-line, too, while further earnings-driving purchases are expected in the near future.

The number crunchers expect Reckitt Benckiser to enjoy earnings growth of 3% in 2015 before accelerating thereafter, leaving the business dealing on a high P/E multiple of 24 times. But I believe the exceptional brand strength of Reckitt Benckiser’s products justifies this premium, enabling the business continue punching solid sales growth even in times of wider macro pressures. On top of this, a projected dividend of 122.2p per share creates a very handy yield of 2.1%, too.

AstraZeneca

Pills play AstraZeneca (LSE: AZN) continues to suffer heavily from revenues-crushing patent losses across key products. Renewed concerns over this issue have pushed share prices steadily lower since the spring and, despite a mild recovery more recently, the stock is currently 2% lower from levels printed at the start of August.

The pharmaceuticals giant has suffered three consecutive earnings losses thanks to stagnating revenues, and an additional dip — albeit by a much-milder 2% — is currently forecast for 2015 as generic competition to labels like Crestor and Nexium eats into the top line. Still, the business has invested vast sums into accelerating its pipeline and bringing out the next wave of sales drivers, while its vast lab-building programme across Europe and US promises to further enhance its development work.

Current earnings projections for 2015 leave AstraZeneca dealing on a P/E rating of 15.1 times, a decent entry point given AstraZeneca’s strong long-term earnings outlook. And when you throw in a predicted dividend of 280 US cents per share — matching the reward of the past four years but still yielding a handsome 4.4% — I believe the medicines maker provides plenty of bang for one’s buck.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£2k in savings? Consider putting it here for maximum passive income

Where’s the best place to park a £2k lump sum for maximum passive income? This Fool knows exactly where his…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

Where will the ITV share price go in 2025? Here’s what the experts say

The ITV share price has been heading up and down as the TV producer and broadcaster has been making the…

Read more »

Investing Articles

3 rules I followed to start investing

Christopher Ruane shares a trio of considerations he used to start investing in the stock market -- and continues to…

Read more »

Investing Articles

UK investors are obsessed with Nvidia stock! Here’s why

This writer considers a few reasons why Nvidia stock has gone up so dramatically in recent years and whether he'd…

Read more »

Investing Articles

Cheap FTSE 100 shares to consider buying after the Black Friday sales

Whatever bargains retailers are offering for Black Friday, stock brokers aren't joining in. I reckon I see enough cheap shares…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

P/E ratio of 6! Is the Centrica share price a bargain?

This writer reckons the current Centrica share price could be a real bargain. But as a former shareholder, will he…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What sort of British companies has Warren Buffett invested in – and why?

Warren Buffett has fished on both sides of the pond over the decades in a hunt for bargain shares. Our…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Here’s how I’m investing in dividend shares to aim for long-term wealth

Our writer plans to turn investments in dividend shares into a retirement pot by implementing a structured, long-term approach.

Read more »